An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu) in the Treatment of Infants 0 to less than 12 Months of Age With Confirmed Influenza Infection.

Trial Profile

An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu) in the Treatment of Infants 0 to less than 12 Months of Age With Confirmed Influenza Infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Oseltamivir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors Roche
  • Most Recent Events

    • 21 Dec 2012 The US FDA extended the approval of oseltamivir to include infants 2 weeks of age and older, based on this and another study, according to a Genentech media release.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2012 Planned number of patients changed from 84 to 85 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top